This article is part of Pulmonology Advisor‘s coverage of the ACAAI 2018 meeting, taking place in Seattle, Washington. Our staff will report on medical research related to allergy, asthma, and more conducted by experts in the field. Check back regularly for more news from ACAAI 2018.

SEATTLE — Reinitiation of treatment is well tolerated in patients who experience a treatment interruption while taking a standardized quality house dust mite sublingual immunotherapy tablet, according to study results presented at the Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology, held November 15-19, 2018, in Seattle.


Continue Reading

Safety data from 2 trials of the standardized quality house dust mite sublingual immunotherapy tablet were analyzed. Adverse events were compared between patients who experienced a treatment interruption of ≥2 consecutive days and those who had no interruption.

Of the 1565 study participants, 783 were in the sublingual immunotherapy group and 782 were in the placebo group. Treatment interruption rates were similar between groups, with 60.7% (n=476) in the treatment group and 64% (n=501) in the placebo group experiencing a treatment interruption for ≥2 consecutive days. The proportion of patients who experienced adverse events at any point after treatment reinitiation was similar between active and placebo groups at 29% and 26%, respectively. Adverse events were determined to be mild or moderate in severity. No systemic allergic reactions, epinephrine administrations, or severe local swellings were reported after treatment reinitiation.

The most frequently reported adverse events after reinitiation were oral pruritus (8%), throat irritation (8%), and ear pruritus (7%). Corresponding rates for the placebo group were 1%, 2%, and 1%, respectively.

The researchers wrote, “Safety data after short-term interruption of [standardized quality house dust mite sublingual immunotherapy] tablet treatment do not indicate a safety signal after tablet re-initiation.” They added, “The safety profile after long-term treatment interruption was not determined.”

Visit Pulmonology Advisor‘s conference section for continuous coverage from ACAAI 2018

Reference

Tilles S, Nelson H, Prenner B, Maloney J, Mosbech Smith I, Nolte H. Adverse event profile of SQ house dust mite sublingual immunotherapy tablet after treatment interruption. Presented at: the Annual Scientific Meeting of the American College of Asthma, Allergy, and Immunology; November 15-19, 2018; Seattle, WA. Abstract A450.